Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Colitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Colitis - Pipeline Review, H1 2016', provides an overview of the Colitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects - The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Colitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Colitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Colitis Overview 10 Therapeutics Development 11 Pipeline Products for Colitis - Overview 11 Pipeline Products for Colitis - Comparative Analysis 12 Colitis - Therapeutics under Development by Companies 13 Colitis - Therapeutics under Investigation by Universities/Institutes 15 Colitis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Colitis - Products under Development by Companies 19 Colitis - Products under Investigation by Universities/Institutes 20 Colitis - Companies Involved in Therapeutics Development 21 Aerpio Therapeutics, Inc. 21 Ajinomoto Pharmaceuticals Co., Ltd. 22 Akebia Therapeutics, Inc. 23 Amorepacific Corporation 24 Bayer AG 25 Bristol-Myers Squibb Company 26 Dr. Falk Pharma GmbH 27 Galapagos NV 28 Immuron Limited 29 Innate Pharma S.A. 30 Peptinov SAS 31 Pfizer Inc. 32 Prokarium Limited 33 Protalix BioTherapeutics, Inc. 34 RDD Pharma Ltd. 35 Saniona AB 36 Synovo GmbH 37 Colitis - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 AcTMP-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AKB-4924 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AKB-6899 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AN-346 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Antibodies to Inhibit Heparanase for Cancer - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Antibody for Colitis - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 APY-0201 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BC-1215 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 BMS-986104 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 budesonide - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Clostridium difficile vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CSY-0073 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 etanercept biosimilar - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 filgotinib - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 IMM-124E - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IPH-33 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 mesalamine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NK-007 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 PAC-14028 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PF-06425090 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PPV-06 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 RDD-2007 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule for Colitis - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Synthetic Peptides to Inhibit Panx1 for Colitis - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Vaccine to Target Interleukin 12 and Interleukin 23 for Colitis - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Vaccine to Target Interleukin-23 for Colitis - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 ZK-216348 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Colitis - Recent Pipeline Updates 85 Colitis - Dormant Projects 97 Colitis - Discontinued Products 100 Colitis - Product Development Milestones 101 Featured News & Press Releases 101 Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA 101 Appendix 102 Methodology 102 Coverage 102 Secondary Research 102 Primary Research 102 Expert Panel Validation 102 Contact Us 102 Disclaimer 103
List of Tables Number of Products under Development for Colitis, H1 2016 11 Number of Products under Development for Colitis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 omparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Colitis - Pipeline by Aerpio Therapeutics, Inc., H1 2016 21 Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2016 22 Colitis - Pipeline by Akebia Therapeutics, Inc., H1 2016 23 Colitis - Pipeline by Amorepacific Corporation, H1 2016 24 Colitis - Pipeline by Bayer AG, H1 2016 25 Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2016 26 Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 27 Colitis - Pipeline by Galapagos NV, H1 2016 28 Colitis - Pipeline by Immuron Limited, H1 2016 29 Colitis - Pipeline by Innate Pharma S.A., H1 2016 30 Colitis - Pipeline by Peptinov SAS, H1 2016 31 Colitis - Pipeline by Pfizer Inc., H1 2016 32 Colitis - Pipeline by Prokarium Limited, H1 2016 33 Colitis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 34 Colitis - Pipeline by RDD Pharma Ltd., H1 2016 35 Colitis - Pipeline by Saniona AB, H1 2016 36 Colitis - Pipeline by Synovo GmbH, H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Stage and Target, H1 2016 40 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Colitis Therapeutics - Recent Pipeline Updates, H1 2016 85 Colitis - Dormant Projects, H1 2016 97 Colitis - Dormant Projects (Contd..1), H1 2016 98 Colitis - Dormant Projects (Contd..2), H1 2016 99 Colitis - Discontinued Products, H1 2016 100
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
